In Brief House Energy and Commerce Committee Democratic leaders urge FDA to advance clinical trial diversity efforts February 23, 2024Vol.50 No.08
Drugs & Targets Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma February 23, 2024Vol.50 No.08
Drugs & Targets FDA OCE annual report lists 83 cancer therapeutic approvals in 2023 February 23, 2024Vol.50 No.08
Drugs & Targets FDA approves Onivyde for first-line treatment of metastatic pancreatic adenocarcinoma February 16, 2024Vol.50 No.07
Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
Regulatory News FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies February 02, 2024Vol.50 No.05By Alexandria Carolan
Guest Editorial Reflecting on Janet Woodcock’s retirement from FDA January 26, 2024Vol.50 No.04By Ellen V. Sigal
Drugs & Targets FDA approves Balversa for locally advanced or metastatic urothelial carcinoma January 26, 2024Vol.50 No.04
